2012 Fiscal Year Final Research Report
Genomic and epigenetic analysis for immune responses in patients with prostate cancer
Project/Area Number |
22591782
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Kurume University |
Principal Investigator |
NOGUCHI Masanori 久留米大学, 先端癌治療研究センター, 教授 (10140691)
|
Co-Investigator(Renkei-kenkyūsha) |
KOMATSU Masakazu 久留米大学, 医学部, 講師 (50343687)
|
Research Collaborator |
MORIYA Fukuko 久留米大学, 医学部, 助手 (80449917)
|
Project Period (FY) |
2010 – 2012
|
Keywords | 前立腺がん / がんワクチン / 遺伝子発現 / ゲノム解析 / バイオマーカー |
Research Abstract |
We characterized the gene expression profiles in peripheral blood of vaccinated patients to identify biomarkers to predict patient prognosis. Peripheral blood was obtained from advanced castration-resistant prostate cancer patients, who survived for >900 days (long-term survivors, n . 20) or died within 300 days (short-term survivors, n . 20) after treatment with personalized peptide vaccination. Gene expression profiles inprevaccination and postvaccination peripheral blood mononuclear cells (PBMCs) were assessed by DNA microarray. There were no statistically significant differences in the clinical or pathological features between the 2 groups. Microarray analysis of prevaccination PBMCs identified 19 genes that were differentially expressed between the short-term and long-term survivors. Among the 15 up-regulated genes in the short-termsurvivors, 13 genes, which were also differentially expressed in postvaccination PBMCs, were associated with gene signatures of granulocytes. Wha set of 4 differentially expressed genes were selected as the best combination to determine patient survival, prognosis was correctly predicted in 12 of 13 patients in a validation set (accuracy, 92%). These results suggested that abnormal granulocytes present in the PBMC faction may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination. Gene expression profiling in peripheral blood might thus be informative for devising better therapeutic strategies by predicting patient prognosis after cancer vaccines.
|
Research Products
(18 results)
-
-
-
-
[Journal Article] Personalized peptide vaccination in patients with refractory non-small cell lung cancer.2012
Author(s)
Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S.
-
Journal Title
International Journal of Oncology
Volume: 40
Pages: 1492-1500
-
[Journal Article] Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination.2012
Author(s)
Komatsu N, Matsueda S, Tashiro K, IojiT, Shichijo S, Noguchi M, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T.
-
Journal Title
Cancer
Volume: 15
Pages: 3208-3221
-
-
[Journal Article] Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24,-A31 and -A33)-positive patients with advanced cancer.2011
Author(s)
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K.
-
Journal Title
Experimental and therapeutic medicine
Volume: 2
Pages: 109-117
-
[Journal Article] A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin.2011
Author(s)
Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K.
-
Journal Title
BJU Int
Volume: 108
Pages: 831-838
-
[Journal Article] Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.2011
Author(s)
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh Uhi, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K.
-
Journal Title
Cancer Biology & Therapy
Volume: 12
Pages: 1266-79
-
-
-
-
-
-
-
-
-